Scroll Top

Developing a novel cross-protective, inactivated vaccine against non-typeable Haemophilus influenzae.

Developing a novel cross-protective, inactivated vaccine against non-typeable Haemophilus influenzae.

Developing a novel cross-protective, inactivated vaccine against non-typeable Haemophilus influenzae

Bridging University and Industry Engagement via the National Industry PhD Program. The First project kicks-offs at the University of Adelaide!

I am thrilled to announce that the FIRST project under the Australian Government Department of Education‘s National Industry PhD Program held its kick-off meeting today at the University of Adelaide. A big thank you to Abdul Bais Abbasi and Mark Neuendorf for arranging today’s meeting and facilitating the program at the University of Adelaide.

Join me in congratulating Doctoral Student Carla Gallasch, Dr. Erin Brazel and Prof Tim Hirst in being granted one of the 15 Industry Linked awards in the inaugural round of the program. Carla, under the supervision of Erin, Dr. Mohammed Alsharifi, Dr. claudia trappetti and Tim, will be undertaking research to develop a new vaccine that could help ward off painful ear infections in children.

For more information about the amazing work that the University of Adelaide and GPN Vaccines are undertaking, see this Channel 9 News story: https://lnkd.in/g3EGd4Ej)

🔗 Want to learn more about the National Industry PhD Program or thinking of applying? Check out the program details here: https://lnkd.in/gpVsGZZ6

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.